Trial Information
 

Summary: Phase III Double Blind Clinical Trial Of OvaRex® for Late Stage Ovarian Cancer, following primary therapy.

Study Description

This study will compare the time to disease relapse between OvaRex® monoclonal antibody treated patients and placebo-treated patients. This study will also compare assessments of survival, quality of life, immune response and safety between active and placebo groups. A detailed explanation can be provided by investigators conducting this trial.

You may be eligible to participate in this study if you:

• Are female, 18 Years and above
• Have stage III/IV ovarian cancer
• Have had elevated levels of CA125
• Have had no more than one debulking surgery
• Have had a complete clinical response to front-line surgery and chemotherapy
  • Patients must have received chemotherapy that included a platinum compound and a taxane following appropriate staging procedures; front-line treatment can include no more than 8 cycles of chemotherapy
  • Patients must have had microscopic or small diameter ( =< 2 cm) residual disease following primary de-bulking surgical procedure
• Are able to commence this study within 4-12 weeks of completing last dose of front line chemotherapy

You are not eligible to participate in this study if you:

• Have a known allergy to murine proteins or have had a documented anaphylactic reaction to any drug, or a known hypersensitivity to diphenhydramine or other antihistamines of similar chemical structure
• Have had a splenectomy
• Have received other investigational drugs within 30 days of enrollment

 

Contact: Michelle Elliot Southwest Regional Cancer Center Located in: Austin, TX 78705 Telephone: 512-421-4183 Email: melliot@swrcc.com   Profile Page: Southwest Regional Cancer Center, Austin, TX

---

If you would like to learn more about participating in this study, please send an e-mail message using the form below. 

Name:
Address:
City:
State:
Zip:
Phone:
Email address:
Message: